Imagine if we could slow down brain aging and potentially prevent Alzheimer’s disease by targeting a single enzyme. Sounds like science fiction, right? But here’s where it gets groundbreaking: researchers have discovered that the OTULIN enzyme, long known for its role in regulating the immune system, is also a key driver of tau formation—a protein notorious for its involvement in Alzheimer’s and other neurodegenerative diseases. And this is the part most people miss: OTULIN might just be the master regulator of brain aging itself.
Scientists at the University of New Mexico (UNM) have uncovered a surprising dual role for OTULIN. While it’s traditionally recognized for managing inflammation and cellular waste removal, their study reveals it also fuels the production of tau, a protein that, when misbehaving, leads to brain inflammation and aging. This discovery could pave the way for revolutionary treatments targeting Alzheimer’s and related disorders. But here’s the controversial part: if OTULIN is such a central player, could targeting it come with unforeseen risks in other brain functions? More on that later.
In their research, published in Pharmaceutical Research Perspectives (https://bpspubs.onlinelibrary.wiley.com/doi/10.1002/prp2.70186), the team demonstrated that deactivating OTULIN—either through a custom-designed molecule or gene knockout—effectively stops tau production and clears it from neurons. These experiments were conducted on two types of cells: one from a patient with late-onset Alzheimer’s and another from a human neuroblastoma cell line commonly used in neuroscience. The results were striking—neurons remained healthy even without tau, challenging the long-held belief that tau is essential for neuronal survival.
Dr. Karthikeyan Tangavelou, a senior scientist in Dr. Kiran Bhaskar’s lab at UNM, emphasizes, ‘Pathological tau is the main culprit in both brain aging and neurodegenerative diseases. By targeting OTULIN, we can potentially restore brain health and prevent aging.’ But this raises a thought-provoking question: If tau isn’t necessary for neuronal health, why has it been so deeply implicated in disease? Could its role be more complex than we’ve assumed?
OTULIN, short for ‘OTU deubiquitinase with linear linkage specificity,’ is a multitasking protein. While its role in inflammation and autophagy (cellular waste removal) was already known, its unexpected influence on tau production was a serendipitous discovery. Tangavelou calls it ‘a groundbreaking finding that could help solve a complex puzzle in neurological diseases and brain aging.’
Normally, tau stabilizes microtubules, which provide structure to neurons. However, when tau undergoes abnormal phosphorylation, it forms neurofibrillary tangles—a hallmark of over 20 neurodegenerative conditions known as tauopathies. Interestingly, as therapies targeting amyloid beta plaques (once considered the primary culprit in dementia) have shown limited success, tau has emerged as a more promising target. Bhaskar’s lab has even developed a vaccine to prevent toxic tau accumulation, with plans for patient trials.
But here’s where it gets controversial: While OTULIN’s role in neurons is clear, its function in other brain cells, like microglia, remains a mystery. ‘If there’s no OTULIN in microglia, it might cause auto-inflammation,’ Tangavelou notes. This uncertainty highlights the need for caution in targeting OTULIN as a therapeutic. The team is now testing OTULIN’s function across different brain cell types to refine its potential as a treatment for various brain disorders.
The study also revealed that suppressing OTULIN affects mRNA signaling and alters the expression of numerous genes, particularly those involved in inflammation. ‘OTULIN is likely the master regulator of brain aging because it controls RNA metabolism,’ Tangavelou explains. ‘Knocking out its gene changes dozens of genes, mostly in the inflammatory pathway.’
Using cutting-edge tools like CRISPR gene editing, pluripotent stem cell induction, bulk RNA sequencing, and computational drug design, the researchers developed a small molecule that inhibits OTULIN. This imbalance between protein synthesis and degradation, Tangavelou notes, could be a key driver of brain aging.
This discovery opens exciting avenues for future research. The team is now exploring OTULIN’s role in brain aging, with the ultimate goal of reversing it. But here’s the question we leave you with: If OTULIN is such a powerful regulator, could targeting it have unintended consequences in other cellular processes? Share your thoughts in the comments—let’s spark a discussion!
